Walgreens Boots Alliance, Inc. Class Action Lawsuit - WBA
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
The Walgreens class action lawsuit seeks to represent purchasers of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) common stock between July 1, 2021 and June 26, 2024, inclusive (the “Class Period”). Captioned Westchester Putnam Counties Heavy & Highway Laborers Local 60 Benefits Fund v. Walgreens Boots Alliance, Inc., No. 24-cv-08559 (N.D. Ill.), the Walgreens class action lawsuit charges Walgreens and certain of Walgreens’ top current and former executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Walgreens class action lawsuit, please provide your information in the form on this page. You can also contact attorney J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Walgreens class action lawsuit must be filed with the court no later than November 18, 2024.
CASE ALLEGATIONS: Walgreens is a global company that delivers retail and pharmacy, and healthcare services.
The Walgreens class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) despite repeated assurances, Walgreens was not disciplined about deploying capital to grow its U.S. Healthcare segment and did not know how to work with and scale the VillageMD model; (ii) Walgreens was not able to profitably scale VillageMD to support Walgreens’ long-term growth initiatives; (iii) Walgreens’ rollout of VillageMD clinics was not going according to plan; (iv) Walgreens’ U.S. Healthcare segment was experiencing slower growth than expected because Walgreens had oversaturated markets with VillageMD clinics, leading these newly created medical clinics to be understaffed and see fewer patients; and (v) Walgreens executives had failed to manage investor expectations regarding the negative impact that the VillageMD expansion would have on Walgreens’ short-term profits, overstatement of the value of VillageMD, and the risk that Walgreens would be forced to divest part or all of its stake in VillageMD.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Walgreens common stock during the Class Period to seek appointment as lead plaintiff in the Walgreens class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Walgreens class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Walgreens class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Walgreens class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig.